In 2002, activating mutations in the gene encoding the serine/threonine kinase BRAF were identified by the Cancer Genome Project (Sanger Centre, UK) in a subset of human cancers, including about 50% of malignant melanomas (Davies et al, 2002). This evidence concerns the gene MARK2 and cancer.